vTv Therapeutics Inc.
4170 Mendenhall Oaks Parkway
Tel: 336-841-0300 ext 100
67 articles with vTv Therapeutics Inc.
vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study
Results Found TTP399 Demonstrated a Statistically Significant Improvement in HbA1c Compared to Placebo without Hypoglycemia or Hyperlipidemia
12/26/2018As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle.
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
vTv Therapeutics Inc. today announced that company management will present a corporate overview at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City.
vTv Therapeutics Inc. today reported financial results for the third quarter that ended September 30, 2018, and provided an update on recent achievements and upcoming events.
vTv Therapeutics Inc. today announced that The NASDAQ Stock Market LLC (“Nasdaq”) has approved the Company’s application to list its Class A Common Stock on The Nasdaq Capital Market.
vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer’s and Diabetes at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Subgroup Analysis Indicates Potential Benefit of Treatment with Azeliragon for Patients with Type 2 Diabetes and Alzheimer’s Disease
vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Results of the Azeliragon Phase 3 STEADFAST Trial to be Presented during Oral Session
vTv Therapeutics Inc. reported financial results for the second quarter that ended June 30, 2018, and provided an update on recent achievements and upcoming events.
vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions
American Diabetes Association’s 78th Scientific Sessions is held in Orlando, Fla., June 22–26, 2018.
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
vTv Therapeutics reported the second part of its Phase III Alzheimer’s disease study failed to meet co-primary efficacy endpoints.
vTv Therapeutics Inc. today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints.
vTv Therapeutics Announces Licensing Agreement with Newsoara Biopharma Co. Ltd. to Rights for vTv’s PDE4 Inhibitor in China and Other Pacific Rim Territories
vTv Therapeutics will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products.
North Carolina-based vTv Therapeutics revealed some potential hope for Alzheimer’s patients from its Phase III azeliragon study despite the drug failing to meet primary endpoints in April.
Only days after UK-based Mereo BioPharma canceled its plans for an initial public offering (IPO) on the Nasdaq Global Market, Framingham, Massachusetts-based Alzheon dropped its IPO plans.
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Yet another Alzheimer’s drug has failed in late-stage clinical trials. vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in its Phase III STEADFAST clinical trial. It was being evaluated in patients with mild Alzheimer’s disease.
vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
Simplici-T1 is an adaptive Phase 1b/2 study being conducted with support from JDRF.
vTv Therapeutics Reports 2017 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights
“We made tremendous progress across the spectrum of our Alzheimer’s and diabetes programs this past year, and look forward to continuing this momentum in 2018 as we anticipate reporting topline results in April from Part A of our Phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer’s disease,” said Steve Holcombe, president and CEO of vTv Therapeutics.